|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:adverse_effect_monitoring
|
required during treatment
|
|
gptkbp:approves
|
gptkb:U._S._Food_and_Drug_Administration
June 2021
|
|
gptkbp:clinical_trial
|
Phase 3
EMERGE
ENGAGE
disputed efficacy
|
|
gptkbp:clinical_use
|
early Alzheimer's disease
|
|
gptkbp:controversy
|
mixed clinical trial results
|
|
gptkbp:developed_by
|
gptkb:Biogen
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
ongoing treatment
|
|
gptkbp:economic_impact
|
significant controversy in healthcare
|
|
gptkbp:eligibility
|
must meet specific criteria
|
|
gptkbp:fdaapproval_type
|
accelerated approval
|
|
gptkbp:financial_support
|
available through Biogen
|
|
gptkbp:funding
|
public and private funding
|
|
gptkbp:healthcare
|
neurologists
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aduhelm
|
|
gptkbp:indication
|
gptkb:neurodegenerative_diseases
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:market_launch
|
gptkb:2021
|
|
gptkbp:marketed_as
|
gptkb:brand
|
|
gptkbp:mechanism_of_action
|
reduces amyloid plaques
|
|
gptkbp:patient_education
|
important for treatment understanding
|
|
gptkbp:patient_population
|
Alzheimer's patients
|
|
gptkbp:pharmacokinetics
|
monoclonal antibody pharmacokinetics
amyloid plaque reduction
|
|
gptkbp:price
|
approximately $56,000 per year
|
|
gptkbp:provides_guidance_on
|
Alzheimer's treatment guidelines
|
|
gptkbp:public_perception
|
mixed reviews
|
|
gptkbp:publication
|
multiple peer-reviewed articles
|
|
gptkbp:regulatory_compliance
|
ongoing scrutiny
controversial approval
|
|
gptkbp:research_focus
|
Alzheimer's treatment
|
|
gptkbp:route_of_administration
|
intravenous infusion
|
|
gptkbp:service_frequency
|
monthly
|
|
gptkbp:side_effect
|
dizziness
nausea
confusion
headaches
brain swelling
|
|
gptkbp:target_audience
|
mild cognitive impairment
|
|
gptkbp:targets
|
amyloid beta protein
|
|
gptkbp:treatment
|
uncertain long-term benefits
|
|
gptkbp:type_of_insurance
|
varies by provider
|
|
gptkbp:bfsParent
|
gptkb:Biogen_Inc.
gptkb:Aducanumab
|
|
gptkbp:bfsLayer
|
5
|